Skip Navigation LinksHome > March 2012 - Volume 112 - Issue 3 > The Efficacy of Fenofibrate is in Question
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000412634.70645.1e
Drug Watch

The Efficacy of Fenofibrate is in Question

Aschenbrenner, Diane S. MS, RN

Collapse Box


* The Food and Drug Administration is requiring the manufacturer of fenofibric acid (Trilipix), also called fenofibrate, to complete a clinical trial to determine the drug's efficacy in reducing cardiovascular events in patients with type 2 diabetes who are already taking a statin.

* This decision follows the outcome of a clinical trial that found that the combination of fenofibric acid and simvastatin (Zocor) was no better than simvastatin alone in minimizing cardiovascular risk.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics